-
Data of Merck's pembrolizumab for adjuvant therapy after complete resection of high-risk stage II melanoma patients announced
Time of Update: 2021-11-16
, Kenilworth, New Jersey, USA) first announced its PD-1 inhibitor pembrolizumab[1] Data from the Phase III clinical trial KEYNOTE-716 for the adjuvant treatment of patients with high-risk phase II melanoma after complete resection .
-
16 exclusive Chinese patent medicines to grab the TOP20!
Time of Update: 2021-11-16
Pediatric Chinese patent medicine increased by 87%, Yang Zijiang became the "big brother"Sales of proprietary Chinese medicines in public hospitals in key cities (unit: ten thousand yuan)Source: Mi Nei. com's key city public hospital terminal competition patternAffected by the epidemic and policies, the market size of proprietary Chinese medicines in public hospitals in key cities will decline significantly in 2020, of which Q1 will decline by nearly 30% in 2020 .
-
Eleven Years of "Pharmaceuticals": Online Digital Drive of Pharmaceuticals, Business Empowerment, Helping Pharmaceutical Enterprises to Transform and Upgrade
Time of Update: 2021-11-16
Provide accurate matching services and build a supply-demand docking platformBuild a smart medicine business school and build a knowledge sharing ecosystem in the pharmaceutical industryAt the beginning of 2021, "Pharmaceutical Online" relied on the rich experience accumulated by the website platform in the past 11 years to integrate resources of existing conference products and upgraded to become the "Intelligent Pharmacy Business School" to create social, learning, and sharing scenarios for the majority of pharmaceutical industry professionals.
-
In-depth analysis of Hengrui's innovative drug design case to explore the golden road of "Yao Mao"
Time of Update: 2021-11-16
In the patent published in 2021 (CN 113004303), a class of pyrimidooxazine tricyclic derivatives are mentioned as ATR kinase inhibitors; Hengrui followed AZD-6738.
In another ATR inhibitor patent of Hengrui (CN 113135942 A), the best possible compound 3 is obtained from AZD-6738 backbone transition, isosteric, and ring closure.
-
FDA Approves New Coronavirus Vaccine "Mixed Fighting" Enhanced Vaccination Program
Time of Update: 2021-11-16
The authorization for Moderna's new crown vaccine allows a single dose of Moderna booster vaccine (dose halved) in people who have completed two doses of vaccination for at least 6 months .
-
Microchip's new diabetes drug sitaglipta sodium is approved for listing in China
Time of Update: 2021-11-16
According to the NMPA official website, as a new PPAR full agonist, sitaglipta sodium can not only control blood sugar in the treatment of type 2 diabetes, but also treat the lipid and energy metabolism disorders that are usually associated with patients, thereby benefiting the heart.
-
Winbond Health's wholly-owned subsidiary methylprednisolone sodium succinate for injection passed the consistency evaluation
Time of Update: 2021-11-16
On October 26, Winbond Health issued an announcement stating that its wholly-owned subsidiary Winbond Pharmaceuticals had recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for injection of methylprednisolone sodium succinate.
-
"Yiwu Market" among pharmaceutical companies?
Time of Update: 2021-11-16
According to the agreement, Zai Lab will obtain the exclusive developer and commercialization rights for Retifanlimab blood and solid tumor indications in Greater China (including Hong Kong, Macau and Taiwan), and Incyte will receive a down payment of US$17.
-
First in class oral complement C5aR inhibitor approved in Japan
Time of Update: 2021-11-16
Avacopan uses a novel and highly targeted mechanism of action in the treatment of ANCA-related vasculitis and other complement-driven autoimmune and inflammatory diseases .
On July 6 this year, ChemoCentryx announced that the PDUFA target date for avacopan's new drug application in the United States has been extended to October 7, 2021 .
-
Guhan Biology, a wholly-owned subsidiary of Tus Pharmaceuticals, and Tus Guhan Industrial Park completed the deregistration
Time of Update: 2021-11-16
Subsidiaries "Hunan Guhan Biological Technology Co.
The company recently received the notice of approval to cancel the registration of the above two subsidiaries issued by the Hengyang Market Supervision Administration .
The deregistration procedures for "Hunan Guhan Biological Technology Co.
-
The IND of APL-1202 and BeiGene's combined neoadjuvant treatment of MIBC is approved by CDE
Time of Update: 2021-11-16
Shanghai, October 13, 2021/PRNewswire/ - Yahong Pharmaceutical announced today that its oral drug APL-1202 and BeiGene Baizean® (tislelizumab) combined with neoadjuvant treatment of muscle invasion The New Drug Clinical Research Application (IND) for bladder cancer (MIBC) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China .
-
AbbVie JAK inhibitor reaches two primary endpoints of Phase 3 clinical trials
Time of Update: 2021-11-16
html[2] AbbVie's upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic Axial Spondyloarthritis.
-
Helixangyuan sincerely invites customers and partners to participate in the 61st Chengdu Pharmaceutical Machinery Exhibition in 2021
Time of Update: 2021-11-16
Beijing, October 14, 2021/PRNewswire/ - Helixangyuan will participate in the 61st (Autumn 2021) National Pharmaceutical Machinery Expo in Chengdu, Sichuan on November 2-4, 2021.
-
839 pharmacies Dashenlin accepted
Time of Update: 2021-11-15
In the first three quarters of this year, Dashenlin had 29 investment mergers and acquisitions, involving a total of 839 stores .
15 percentage points from the previous year; Chinese ginseng medicinal materials this year The performance of the first three quarters was also good, with total revenue of 1.
-
FDA accepts Novartis CAR-T cell therapy Kymriah supplementary biologics license application
Time of Update: 2021-11-15
CompilationTom LeeRecently, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have respectively accepted Novartis’ Kymriah (tisagenlecleucel) as a treatment for relapsed or refractory (r/r) follicular lymphoma (FL) adults The patient’s application for review .
-
The 15th Zhang Zhongjing Medical Culture Festival Traditional Chinese Medicine Industry Development Forum was held in Nanyang
Time of Update: 2021-11-15
Recently, the 15th Zhang Zhongjing Medical Culture Festival and the 9th Zhongjing Forum were held in Nanyang, Henan. Through forums + exhibitions, project signing, and popularization of Chinese medi
-
Harbin Sanlian Ondansetron Hydrochloride Injection Passed the Consistency Evaluation of Generic Drugs
Time of Update: 2021-11-15
On October 31, Harbin Sanlian issued an announcement stating that the company has recently received a supplementary drug application approval notice issued by the National Medical Products Administrat
-
The domestic medical device industry continues to develop well, and machinery companies need to break through the homogeneous competition
Time of Update: 2021-11-15
In recent years, the development of China's medical device industry has clearly entered the fast lane, and the performance of many machinery companies is also developing continuously .
In addition to Mindray Medical, on October 15th, A-share listed company Ingram Medical also issued a three-quarter report performance forecast.
-
Domestic biomedical talents are popular, and the proportion of mid-to-high-end talents in the high-salary segment has increased significantly
Time of Update: 2021-11-15
Recently, an organization released the "Report on Recruitment of Talents in the Biomedical Field for the First Half of 2021" (the "Report"), showing that the proportion of high-end talents in the biomedical industry has increased significantly .
-
Mid-term clinical failure GSK stops developing anti-GM-CSF monoclonal antibody otilimab to treat COVID-19
Time of Update: 2021-11-15
The data shows that in patients of all ages, compared with standard care (including antiviral therapy and glucocorticoids), a single dose of otilimab + standard care treatment for 28 days failed to improve the survival of patients with severe COVID-19-related lung diseases.
